Updated Story The Senate Finance Committee plans to increase the Medicaid drug rebate cap from 100% of a drug’s average manufacturer price to 125% and remove the cap entirely for new drugs, according to sources following the negotiations. The rebate measure is part of drug-pricing legislation that committee members are negotiating. Brand-drug makers currently pay a base 23.1% rebate to Medicaid, plus inflationary rebates when prices rise faster than the Consumer Price Index-Urban. Medicaid rebates are capped...